Red List

MLTXMoonLake Immunotherapeutics

Healthcare · Biotechnology · small-cap ($1.6B)
-73.7%
from rolling 252-day high of $62.75 set 2025-09-26 · 321d ago
Current
$16.50
Decline depth
-73.7%
Decline σ
4.8σ
TFC
1/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Since it joined the list

$MLTX landed on the list 2026-03-02, down 71.8% from its 52-week high that day — now down -73.7%.

That's 2.0 percentage points deeper than the day it joined.

Decline from the 52-week high as it stood on 2026-03-02 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.

Structural break signals

MLTX qualifies for the Red List on decline depth.

Decline depth
-73.7%
From rolling 252-day high of $62.75, 321d ago. Past the 40% Red List threshold.
Time-frame continuity
1/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Decline sigma
4.8σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (3.92% per day). Past the ≥4σ Watch threshold.

The structural read

What price action says about MLTX.

MLTX qualifies for the Red List on decline depth — down -73.7% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy.

Cross-confirmation: decline sigma also reads 4.8σ over 20 bars.

Upstream TFC read: bearish alignment, current phase daily. Last bar types — daily 3 (red), weekly 2D (red), monthly 2D (red).

Earnings on file: 2026-02-25. Tiering is unaffected by earnings dates — listings reflect price structure only.

Questions about MLTX

What people ask.

Why is MLTX on Broken Stocks?

MLTX qualifies for the Red List on decline depth. It is down -73.7% from its rolling 252-day high of $62.75, set on 2025-09-26 — 321d ago.

Is MLTX a falling knife?

Not by the strict technical definition. MLTX is down -73.7% from its 52-week high, but that high was set 321d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. MLTX is still on the Red List for decline depth, but the freshness component of a falling knife is missing.

Is MLTX a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is MLTX trading inside its 52-week range?

At $16.50, MLTX sits 18.6% of the way from its 52-week low ($5.95) to its 52-week high ($62.75). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has MLTX been declining?

The current 73.7% decline accrued over 321d, which annualizes to roughly -83.8% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does MLTX compare to its sector?

There are 140 other Healthcare tickers on Broken Stocks: 67 Red, 34 Amber, 39 Watch, with 48 showing recovering structural signals. Median sector decline is -35.8% — MLTX's decline is deeper than the sector median.

Does MLTX's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-02-25) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.